Answers are grounded in this paper and cite their sources.
Reducing antimicrobial use in dairy production is a priority within the One Health framework, particularly at dry-off, when intramammary antimicrobials are commonly administered. This prospective non-randomised controlled field trial evaluated the feasibility and udder-health response associated with intramammary platelet lysate (PL) administration at dry-off as a potential antimicrobial-sparing strategy. Autologous PL was produced individually from whole blood collected from dairy cows on 17 commercial farms. A total of 614 quarters were initially enrolled; five were excluded after major mastitis pathogens were detected and farmers opted for antimicrobial treatment, and four were excluded because post-calving follow-up was unavailable, resulting in 605 quarters in the final analytical dataset. Quarters were classified according to SCC-derived linear score (LS) as healthy (LS ≤ 4), low risk (4 < LS ≤ 5), or high risk (LS > 5) and received internal teat sealant alone (SO), antimicrobial plus sealant (AS), or PL plus sealant (PLS). Treatment response was assessed using the change in LS between dry-off and post-calving (ΔLS; dry-off minus post-calving). In healthy quarters, no treatment effect on ΔLS was detected ( p = 0.5638). Among quarters with LS > 4, ΔLS did not significantly differ between AS and PLS ( p = 0.0936), although a numerically higher proportion of high-risk quarters treated with AS returned to the healthy LS category after calving compared with PLS-treated quarters (83.33% vs. 63.89%). No clinical mastitis cases were recorded during the 30-day post-calving monitoring period. Intramammary PL administration at dry-off was feasible under commercial farm conditions, and its effects on ΔLS in quarters with elevated LS did not significantly differ from those observed with antimicrobial therapy. These findings support further investigation of PL as a potential antimicrobial-sparing strategy within selective dry cow therapy, although larger controlled trials are required to establish its efficacy and optimise administration protocols.
No takes yet. Share an insight, caveat, or question.
Rigo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: